OTC:RAPH
Raphael Pharmaceutical Inc.
A pre-revenue OTC pharmaceutical company burning cash on research while leveraging share issuances to offset operational losses.
Key Metrics
Investment Thesis
Bull Case
Investors might consider RAPH for exposure to a potential breakthrough drug pipeline that could yield exponential returns upon regulatory approval and market launch. The current valuation reflects deep distress, offering an entry point below intrinsic value if the company successfully transitions from R&D to commercialization. Strategic partnerships or licensing deals not yet reflected in financials could provide immediate cash infusions and validate the intellectual property portfolio.
Bear Case
The stock is a speculative trap given the massive accumulated deficit of nearly $9M and zero revenue for multiple consecutive years. Continuous share issuances to cover operating losses will lead to perpetual dilution, making existing equity stakes increasingly worthless over time. With current assets barely covering liabilities and negative working capital trends, there is no visible path to solvency without external bailout or successful product sales.
About Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc. (RAPH) is an over-the-counter pharmaceutical entity focused on drug discovery, research and development, and regulatory compliance for niche medical markets. The company currently operates with minimal commercial revenue while directing capital toward high-cost operational expenses and non-cash equity adjustments to fund its pipeline. Despite a significant accumulated deficit and negative operating cash flow, the firm maintains a balance sheet structured to support long-term R&D initiatives rather than immediate profitability.
Analysis
Management Discussion
Management has prioritized survival over profitability, resulting in a net loss of $1.5M driven by operating expenses that exceed revenue generation capabilities. While non-cash adjustments and share-based compensation partially offset cash burn, the company continues to accumulate debt through accrued liabilities relative to its dwindling cash reserves. The financial trajectory indicates a reliance on continuous capital raising rather than organic growth from product sales.
Industry Overview
The pharmaceutical industry for small-cap OTC firms is characterized by high failure rates in R&D and a binary outcome where only successful drugs generate significant profits. Companies in this space often operate as long-term bets on specific therapeutic targets, requiring sustained cash flow from investors until market entry. Regulatory hurdles in drug development create a high barrier to entry but also protect successful products from generic competition once patents expire.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $3.3M | $1.3M | $1.5M |
| Operating Income | $-3.3M | $-1.3M | $-1.5M |
| R&D | $1.2M | $569.0K | $776.0K |
| G&A | $2.1M | $703.0K | $733.0K |
| Stock-Based Comp | $2.3M | $200.0K | $350.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-3.3M | $-1.3M | $-1.5M |
| Income Tax | $41.0K | $12.0K | $10.0K |
| Continuing Ops | $-3.4M | $-1.3M | $-1.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-3.4M | $-1.3M | $-1.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-3.4M | $-1.3M | $-1.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $331.0K | $337.0K | $25.0K |
| Cash & Equivalents | $288.0K | $230.0K | $19.0K |
| Other Current Assets | $43.0K | $107.0K | $6.0K |
| Long-Term Assets | $2.0K | $2.0K | $2.0K |
| PP&E (Net) | — | — | $2.0K |
| Other LT Assets | — | — | $0 |
| Total Assets | $333.0K | $339.0K | $27.0K |
| Current Liabilities | $227.0K | $72.0K | $769.0K |
| Accounts Payable | — | — | $125.0K |
| Other Current Liab | $75.0K | — | $269.0K |
| Long-Term Liabilities | $0 | $534.0K | $0 |
| Total Liabilities | $227.0K | $606.0K | $769.0K |
| Shareholders' Equity | $106.0K | $-267.0K | $-742.0K |
| Paid-In Capital | $6.0M | — | — |
| Retained Earnings | $-6.0M | $-7.3M | $-8.9M |
| Total L&E | $333.0K | $339.0K | $27.0K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-3.4M | $-1.3M | $-1.5M |
| Non-Cash Adjustments | $2.7M | $272.0K | $392.0K |
| Working Capital Changes | $-143.0K | $-191.0K | $595.0K |
| Cash from Operations | $-759.0K | $-1.2M | $-532.0K |
| Cash from Investing | $-2.0K | $0 | $0 |
| Cash from Financing | $896.0K | $1.1M | $321.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $135.0K | $-58.0K | $-211.0K |
| Beginning Cash | $153.0K | $288.0K | $230.0K |
| Ending Cash | $288.0K | $230.0K | $19.0K |
Frequently Asked Questions
How does Raphael Pharmaceutical Inc. make money?
The primary business segment is drug discovery and development, evidenced by substantial R&D expenditures exceeding $700k annually. A secondary segment involves corporate governance and capital raising activities, indicated by significant cash flow from financing and common share issuances used to sustain operations. The third segment covers regulatory affairs and general administrative support required to maintain OTC listing compliance.
What are the main risks for RAPH?
The company faces an existential liquidity risk as operating cash flow is negative and accumulated deficits exceed $8M without commercial revenue streams. Regulatory approval uncertainties pose a significant threat to the R&D pipeline, which incurs high costs with no guaranteed return on investment. Dilution risk remains elevated as the company relies heavily on common share issuances to finance operations, potentially eroding shareholder value. The absence of current assets beyond cash and minimal long-term liabilities creates a fragile structure vulnerable to market volatility.
What is RAPH's competitive advantage?
The company's moat lies in its specialized access to niche therapeutic areas with high unmet medical needs where large competitors have exited. Management has successfully utilized capital markets through share issuances to extend the life of the pipeline without relying on traditional product sales. The firm maintains a lean operational footprint with minimal fixed assets, allowing for flexible resource allocation during early-stage research phases.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.